secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001493152-22-029741
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell loses foreign private issuer status, restates interim financials to U.S. GAAP
--------------------------------------------------------------------------------

- As of July 31, 2022, BriaCell no longer qualifies as foreign private issuer; effective Aug 1, 2022 must file as domestic issuer.
- Restated interim financial statements for Oct 31, 2021, Jan 31, 2022, and Apr 30, 2022 from IFRS to U.S. GAAP.
- Net loss for Q1 FY2022 (Oct 2021) was $27.5M, primarily due to $25.3M warrant remeasurement loss.
- Cash and cash equivalents were $55.5M as of Oct 31, 2021; accumulated deficit $56.7M.
- Company is defending against Alpha Capital Anstalt lawsuit over warrant amendment; believes it will not have to pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315222029741/0001493152-22-029741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315222029741/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-029741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer